Thomson Reuters to Sell Healthcare Subsidiary for $1.25 Billion

By Bizclik Editor
Share

 

Thomson Reuters announced today its plans to sell its healthcare  business to Veritas Capital for $1.25 billion in cash. Expected to close within the next few months, the sale is subject to regulatory approval.

"We are proud of our colleagues who built a very strong Healthcare business," said James C. Smith, chief executive officer of Thomson Reuters. "I know they will continue to serve their customers with the same high standards under new ownership. With the completion of the divestiture, Thomson Reuters will be even more focused on our core global businesses."

Thomson Reuters’ healthcare affiliate excels in providing data, analytics and performance benchmarking solutions to the healthcare industry. Utilized by hospitals, health systems, employers, health plans, government agencies and healthcare professionals, Thomson Reuters healthcare services include leading solution brands such as MarketScan, Advantage Suite, Micromedex, CareDiscovery and ActionOI.

"The Healthcare business of Thomson Reuters is the preeminent healthcare analytics company in the industry today," said Robert McKeon, chairman of Veritas Capital. "The acquisition will provide us with a unique and exciting opportunity to add a truly outstanding business and world-class management team to our portfolio and we look forward to building upon our experience in the healthcare analytics market. We look forward to welcoming the business and its talented employees, including its talented management team led by Mike Boswood, into the Veritas family."

 

SEE RELATED STORIES FROM THE WDM CONTENT NETWORK:

Click here to read the latest edition of Business Review Canada

 

Veritas Capital, a leading private equity investment firm, regularly invests in companies that provide leading products and services to its customers.

"We are excited to become part of Veritas Capital. Veritas is committed to helping us continue to grow and expand our business and our customers should expect the same level of high quality services after the transaction closes," said Mike Boswood, president of the Healthcare business.

Share

Featured Articles

What is Nestlé CEO Laurent Freixe’s Action Plan?

Newly appointed CEO sets out action plan involving separating water brands into standalone business and boosting advertising and marketing spend

Will Mulberry Turn a New Leaf Under CEO Andrea Baldo?

International British luxury brand cuts quarter of head office staff as newly appointed CEO conducts strategic review

Female Board Members of Biggest UK Companies Paid 69% Less

Female board members of FTSE 100 companies are paid 69% less than male counterparts, as they find themselves frozen out of the biggest roles

Is This the Next CEO of LVMH?

Leadership & Strategy

How Burberry’s New CEO Is Going Back to Basics

Leadership & Strategy

Is Bayer CEO Bill Anderson Running Out of Time?

Leadership & Strategy